Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T cell differentiation
Asymmetric division can generate effector and memory CD8 + T cell precursors. Powell and colleagues show asymmetric partitioning of mTORC1 activity upon CD8 + T cell division, which results in distinct metabolic programming of daughter T cells. The asymmetric partitioning of fate-determining protein...
Saved in:
Published in | Nature immunology Vol. 17; no. 6; pp. 704 - 711 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.06.2016
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
ISSN | 1529-2908 1529-2916 1529-2916 |
DOI | 10.1038/ni.3438 |
Cover
Summary: | Asymmetric division can generate effector and memory CD8
+
T cell precursors. Powell and colleagues show asymmetric partitioning of mTORC1 activity upon CD8
+
T cell division, which results in distinct metabolic programming of daughter T cells.
The asymmetric partitioning of fate-determining proteins has been shown to contribute to the generation of CD8
+
effector and memory T cell precursors. Here we demonstrate the asymmetric partitioning of mTORC1 activity after the activation of naive CD8
+
T cells. This results in the generation of two daughter T cells, one of which shows increased mTORC1 activity, increased glycolytic activity and increased expression of effector molecules. The other daughter T cell has relatively low mTORC1 activity and increased lipid metabolism, expresses increased amounts of anti-apoptotic molecules and subsequently displays enhanced long-term survival. Mechanistically, we demonstrate a link between T cell antigen receptor (TCR)-induced asymmetric expression of amino acid transporters and RagC-mediated translocation of mTOR to the lysosomes. Overall, our data provide important insight into how mTORC1-mediated metabolic reprogramming affects the fate decisions of T cells. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Present Address: Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA. Present Address: Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA. Present Address: Department of Research Oncology, MedImmune LLC, Gaithersburg, Maryland, USA. Contributed equally and should be considered co-first authors |
ISSN: | 1529-2908 1529-2916 1529-2916 |
DOI: | 10.1038/ni.3438 |